0 Bewertungen0% fanden dieses Dokument nützlich (0 Abstimmungen)
68 Ansichten9 Seiten
Vasopressin and norepinephrine are used to treat septic shock. Patients with serious adverse events had higher mortality (p 0.01) than patients without serious adverse events.
Vasopressin and norepinephrine are used to treat septic shock. Patients with serious adverse events had higher mortality (p 0.01) than patients without serious adverse events.
Vasopressin and norepinephrine are used to treat septic shock. Patients with serious adverse events had higher mortality (p 0.01) than patients without serious adverse events.
Objective: The frequency, risk factors, and mortality rates of seri- ous adverse events associated with the use of vasopressin and norepinephrine are not clear. The objectives of this study were to determine frequency, risk factors (including candidate gene poly- morphisms), and outcomes of serious adverse events in septic shock patients. Design: Retrospective cohort study using multicenter discovery and single-center validation cohorts. Setting: ICUs at academic teaching centers. Patients: Five hundred ninety-seven patients with septic shock in discovery (Vasopressin and Septic Shock trial) and 533 patients in validation (St. Pauls Hospital) cohorts. Intervention: Vasopressin and norepinephrine for septic shock. Measurements and Main Results: The primary outcome variable was 90-day mortality rates of patients with and without serious adverse events. Secondary outcome variables were the association between vasopressor genotype pathway polymorphisms, plasma vasopressin levels, and serious adverse events. Plasma vasopres- sin concentrations were measured at baseline, 6 hours, 24 hours, 72 hours, and 7 days after vasopressor infusion. Patients with sep- tic shock were genotyped for 268 vasopressor pathway tag sin- gle-nucleotide polymorphisms. Serious adverse events occurred in 10.5% and 9.7% of patients in Vasopressin and Septic Shock trial and St. Pauls Hospital cohorts, respectively. Patients who had serious adverse events had higher mortality (p < 0.01) than patients without serious adverse events (adjusted for age, serum lactate, Acute Physiology and Chronic Health Evaluation II, and maximum dose of norepinephrine day 1) (hazard ratio, 2.97; 95% CI, 2.204.00; p < 0.001 and hazard ratio, 1.89; 95% CI, 1.262.85; p = 0.002 in Vasopressin and Septic Shock trial and St. Pauls Hospital, respectively). There was no difference in the area under the plasma vasopressin concentration curve between patients with and without serious adverse events (p = 0.1). The AA genotype of rs28418396 single-nucleotide polymorphism (near the arginine vasopressin receptor 1b gene) was signifcantly associated with serious adverse events in discovery and valida- tion cohorts (p = 0.001 and p = 0.04, respectively). Conclusion: Serious adverse events associated with vasopres- sin and norepinephrine in patients who have septic shock are associated with increased mortality and morbidity. AA genotype of rs28418396 single-nucleotide polymorphism near the arginine vasopressin receptor 1b gene is associated with serious adverse events. The mechanism of this association requires investigation. (Crit Care Med 2014; 42:18121820) Key Words: arginine vasopressin receptor 1b; norepinephrine; septic shock; serious adverse events; vasopressin I n the latest surviving sepsis guidelines, norepinephrine (NE) is recommended as rst vasopressor and vasopres- sin can be added to NE with intent of either raising mean arterial pressure (MAP) or decreasing NE dosage (1). However, these commonly used vasopressors are associated with serious adverse events (SAEs) (2). Although the hemodynamic status may be improved by vasopressors, several studies of vasopres- sin and NE infusions found the prevalence of adverse drug Copyright 2014 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins DOI: 10.1097/CCM.0000000000000333 *See also p. 1944. 1 Centre for Heart Lung Innovation, St. Pauls Hospital, Vancouver, BC, Canada. 2 Division of Critical Care Medicine, St. Pauls Hospital, University of British Columbia, Vancouver, BC, Canada. Registration: ISRCTN94845869. Supplemental digital content is available for this article. Direct URL cita- tions appear in the printed text and are provided in the HTML and PDF versions of this article on the journals website (http://journals.lww.com/ ccmjournal). Supported, in part, by VASST, Canadian Institutes of Health Research (grant number: MCT 44152). Dr. Boyd is a recipient of a Providence Health Care Research Scholar- ship. Dr. Walley is employed by the University of British Columbia and has stock options with Sirius Genomics. His institution received grant support from the University of British Columbia and Canadian Institutes of Health Research. Dr. Russell served as board member for Sirius Genomics; con- sulted for Ferring Pharmaceutical, Grifols, Medimmune, and Astra Zeneca; lectured for Pfzer; has a patent with the University of British Columbia and Sirius Genomics; and has stock options with Sirius Genomics. His institu- tion received grant support from Ferring Pharmaceutical, Astra Zeneca, Sirius Genomics, and Eli Lilly. Dr. Anantasit has disclosed that he does not have any potential conficts of interest. For information regarding this article, E-mail: jim.russell@hli.ubc.ca Serious Adverse Events Associated With Vasopressin and Norepinephrine Infusion in Septic Shock* Nattachai Anantasit, MD 1 ; John H. Boyd, MD, FRCP(C) 1,2 ; Keith R. Walley, MD, FRCP(C) 1,2 ; James A. Russell, MD, FRCP(C) 1,2 Clinical Investigations Critical Care Medicine www.ccmjournal.org 1813 events ranged from 10% to 72% (36). SAEs of vasopressors include arrhythmias, chest pain, myocardial infarction, cardiac arrest, decreased cardiac output, stroke, limb ischemia, mesen- teric ischemia, and water intoxication (711). SAEs occurred in about 10% of patients in a randomized controlled trial of vaso- pressin versus NE (Vasopressin and Septic Shock trial, VASST), with no difference in frequency between treatment groups (5). The risk of these SAEs in VASST has not yet been investigated. SAEs can lead to death, but it is not well understood whether and to what extent patients who have SAEs associated with vasopressin and NE have an increased risk of death. In addition, SAEs associated with vasopressin or NE infu- sion in patients with septic shock can be difcult to predict. Clinical markers, vasopressin levels, and pharmacogenomic markers could identify patients who have an increased risk of SAEs and the clinician can then avoid or discontinue that drug. Genetic single-nucleotide polymorphisms (SNPs) are important identiable risk factors in patients who may develop SAEs (12). Limited lists of candidate genes in the vasopressin and NE pathways modulate their actions and so could be candidates for evaluation as SNPs predictive of SAEs associated with vaso- pressin and NE. Vasopressin stimulates a family of receptors including arginine vasopressin receptor (AVPR)1a (V1 recep- tor), AVPR1b (V3 receptor), AVPR2 (V2 receptor), oxytocin receptor, and purinergic receptors (13). Vasopressinase (leucyl/ cystinyl aminopeptidase, LNPEP) is associated with mortality and increased vasopressin clearance in septic shock patients (14). NE stimulates adrenergic receptors. The -adrenergic receptor gene (ADR) plays an important role in cardiovascular disease and SNPs of ADR have been associated with mortality of septic shock (15). Furthermore, the angiotensin II signaling pathway gene polymorphisms are associated with outcomes in cardiovascular disorders (16). An angiotensin II type 1 recep- torassociated protein (AGTRAP) polymorphism is associated with mortality in patients with septic shock (17). Our overarching goal was to determine the mortality rate of SAEs associated with vasopressin and NE infusion in patients who have septic shock. We also sought to determine whether commonly available clinical characteristics are associated with an increased risk of developing SAEs. Finally, we hypothesized that SNPs of candidate genes of the vasopressin and NE path- ways and/or plasma arginine vasopressin (AVP) levels could predict SAEs in patients who had septic shock who received vasopressin versus NE infusions. MATERIALS AND METHODS Patients VASST Cohort. We used the VASST cohort as the discov- ery cohort because VASST was a multicenter, randomized, double-blind, controlled trial evaluating the safety and efcacy of vasopressin 0.010.03 U/min versus NE 515 g/min in a total of 778 patients with septic shock. Entry criteria required that eligible patients were older than 16 years, had two of four criteria for systemic inammatory response syndrome (SIRS), had a new proven or suspected infection, had new dysfunction of at least one new organ dysfunction, and had hypotension despite adequate uid resuscitation on a minimum of 5 g/ min of NE at baseline (5). During the initiation and titration of the study drug, the bedside nurse also titrated open-label vasopressors to maintain a constant target MAP. An initial tar- get MAP of 6575 mm Hg was recommended. Of these, 597 patients had complete patient data, DNA available, and were included in the current study. The research ethics boards of all participating institutions approved this trial, and writ- ten informed consent was obtained from all patients or their authorized representatives. The research ethics board at the coordinating center (University of British Columbia) approved the genetic analysis. St. Pauls Hospital Cohort. We used the St. Pauls Hospi- tal (SPH) cohort as a validation cohort because it included patients in whom vasopressin and NE were used in prac- tice. However, vasopressin and NE use were not randomized, blinded, or protocolized. We did a retrospective chart review of patients who admitted at SPHICU with septic shock. Septic shock was dened by infection, the presence of two or more diagnostic criteria for the SIRS, and hypotension despite ade- quate uid resuscitation or requiring vasopressor (18). Vaso- pressin was generally used after patients were already started on NE infusions (as rst vasopressor) usually, when patients were not responsive and needed increased doses of vasopressin. There was no difference in use of vasopressin over the 5 years. Patients admitted to the ICU of SPH in Vancouver, Canada, between July 2000 and January 2004 were screened (n = 1,626). Of these, 533 patients had septic shock at admission, were extensively phenotyped, and had DNA available. Phenotyping and genotyping were not part of routine practice at SPH. The institutional review board at SPH and the University of British Columbia approved the study. This study used discarded blood and anonymized databases, and so the ethics board ruled that consent was not necessary. Denitions SAEs were dened as any severe, life-threatening event tem- porally associated with the use of vasopressin or NE. Acute myocardial ischemia was dened by serum cardiac troponin T above normal plus electrocardiogram (ECG) ndings sug- gesting myocardial ischemia as interpreted by clinical cardi- ologists interpreting ECGs. Tachyarrhythmia was dened as a new onset of atrial brillation. Bradyarrhythmia was dened as a new heart rate below 50 beats/ min which require rapid intervention. Cardiac arrest dened as asystole, ventricular brillation, or pulseless electrical activity. Digital ischemia was dened as the occurrence of new areas of mottled or livido skin in one or more extremities (4). Mesenteric ischemia was dened by evidence of radiographic signs of ischemic bowel on abdominal radiograph as interpreted by clinical radiolo- gists. Cerebrovascular accident was dened as new neurologic decit and acute cerebral infarct or hemorrhage on CT brain. Hyponatremia was dened as a serum sodium level of less than 130 mmol/L. Anantasit et al 1814 www.ccmjournal.org August 2014 Volume 42 Number 8 We evaluated organ dysfunction by calculating days alive and free (DAF) of organ dysfunction (19). Organ dysfunction for each organ system was considered to be present during each 24-hour period if there was evidence of moderate, severe, or extreme organ dysfunction according to the Brussels cri- teria (20). Each day a patient was given 1 if alive and free of organ dysfunction and zero if dead or had organ dysfunction. We also similarly assessed DAF ventilation, vasopressors, and renal support over 28 days. The lowest score possible for each variable was zero and the highest score possible was 28. A low score indicates more organ dysfunction, whereas a high score indicates less organ dysfunction. Plasma Vasopressin Levels Blood for measurement of plasma vasopressin levels was col- lected at baseline, 6 hours, 24 hours, 72 hours, and 7 days in VASST. Plasma vasopressin concentration was measured after extraction on reversed phase column by double anti- body immunoassay (5). This subgroup of 88 patients who had plasma vasopressin concentrations measured (n = 45 in vasopressin group and n = 43 in NE group) had similar clini- cal characteristics to the original VASST cohort (subgroup vs original VASST cohort, median age [yr]: 62 vs 63; male [%]: 60.2 vs 60.9; Acute Physiology and Chronic Health Evalua- tion II [APACHE II]: 26 vs 27; serum lactate [mmol/L]: 2.1 vs 2.2). We calculated the area under the plasma vasopressin concentration-time curve (AUC of the vasopressin levels) of each patient for later group comparisons. Selection of SNPs of Vasopressin and NE Pathway and Genotyping DNA was extracted from the buffy coat of discarded blood samples using a QIAamp DNA maxi kit (Qiagen, Mississauga, ON, Canada) and genotyped using the Illumina Golden Gate assay (Illumina, San Diego, CA). We used genotyping data from Seattle SNPs (http://pga.gs.washington.edu/) and Hap- Map (http://www.hapmap.org/) with an r 2 threshold of 0.65 for SNPs with a minor allele frequency more than 5% to iden- tify tag SNPs. We identied four tag SNPs (AGTRAP) and 16 tag SNPs (ADR) in NE pathway and three tag SNPs (AVPR1a), ve tag SNPs (AVPR1b), 237 tag SNPs (LNPEP), and three tag SNPs (OXTR) in the vasopressin pathway. Primary and Secondary Outcomes The primary outcome was 90-day mortality, and we compared the mortality rates of patients who did or did not have a SAE. We also evaluated whether baseline clinical characteristics dif- fered between patients with or without SAEs. Finally, we also determine whether plasma vasopressin levels and SNPs related to vasopressin and NE were associated with SAEs. Statistical Analysis Statistical analysis was performed using R, version 2.8.1 (http:// www.R-project.org), and SPSS, version 16 (SPSS, Chicago, IL) statistical software packages. We compared patients who had developed SAEs with no SAEs and tested for differences in baseline characteristics and hospital outcomes including DAF of organ dysfunction by using the Mann-Whitney U statistic test for continuous data or a chi-square test for categorical data. Normally distributed continuous variables were described by mean and SD, whereas nonnormally distributed continuous variables were expressed by median and interquartile ranges. Categorical variables were expressed as number of patients and percentage. We tested for Hardy-Weinberg equilibrium using a chi-square test primarily as a data quality check. The Armitage trend test was used for evaluation of the association of SNPs TABLE 1. Serious Adverse Events in Discovery (Vasopressin and Septic Shock Trial) and Validation (St. Pauls Hospital) Cohorts Variable Vasopressin and Septic Shock Trial Cohort (n = 597) (%) St. Pauls Hospital Cohort c
(n = 533) (%) p Myocardial ischemia 12 (2) 14 (2.6) 0.49 Tachyarrhythmias 6 (1) 14 (2.6) 0.039 a Bradyarrhythmias 7 (1.2) 10 (1.9) 0.332 Cerebrovascular accident 2 (0.3) 7 (1.3) 0.093 Unexpected cardiac arrest 7 (1.2) 3 (0.6) 0.349 Digital ischemia 8 (1.3) 3 (0.6) 0.184 Mesenteric ischemia 14 (2.3) 2 (0.4) 0.005 a Hyponatremia 2 (0.3) 0 0.501 Others b 6 (1) 0 0.032 a Total 63 (10.6) 52 (9.7) 0.658 a p < 0.05. b Other events include acute hepatitis, agranulocytosis, pulmonary embolism, seizures, drug error, and drug extravasation from the central venous catheter. c Electrolytes were not reviewed in St. Pauls Hospital cohort. p values are based on Pearson chi-square test. Clinical Investigations Critical Care Medicine www.ccmjournal.org 1815 with presence or absence of SAEs. Kaplan-Meier curves were constructed for comparison of the estimated probability of survival in the two outcome groups and were tested for differ- ence using the log-rank test. We also did an analysis comparing SAE versus no SAE adjusting for important baseline variables using Cox regression analysis. The occurrence of SAE dur- ing hospital stay was considered a time-dependent covariate in the analysis. We tested the above hypotheses in the discov- ery cohort and then took forward only those baseline clinical characteristics and SNPs that were signicant in the discovery cohort for further evaluation in the validation cohort. In all comparisons, p value of less than 0.05 was considered statisti- cally signicant. RESULTS The frequency of SAEs was similar in the discovery and vali- dation cohorts (Table 1). There were 64 SAEs in 63 patients (10.7% of the VASST cohort) and 53 events in 52 patients (9.9% of the SPH cohort). Mesenteric ischemia (2.3%) was the most common SAE in VASST, whereas myocardial ischemia and tachyarrhythmias (2.6%) were the most common SAEs in SPH (Table 1). We found that similar proportions of patients on vaso- pressin versus NE in the discovery and validation cohorts had SAEs. In VASST, 33 of 304 patients who received vasopressin (AVP group) (10.8%) had SAEs and 30 of 293 patients who received NE (NE group) (10.2%) had SAEs. Similarly, in SPH, 14 of 111 patients in AVP group (12.6%) and 38 of 422 patients in NE group (9%) had SAEs. In VASST, patients who had developed SAEs were sig- nicantly older (69 vs 63 yr, p = 0.045) and had a higher ini- tial arterial lactate level (2.8 vs 2.2 mmol/L, p = 0.035) than patients who did not develop SAEs. In addition, patients who had SAEs received signicantly higher (median) NE dose on day 1 than patients without SAEs (20 g/min vs 15 g/min, p = 0.016) (Table 2). In the SPH cohort, patients who had SAEs TABLE 2. Baseline Characteristics of Patients With or Without Serious Adverse Events With Septic Shock in the Discovery (Vasopressin and Septic Shock Trial) and Validation (St. Pauls Hospital) Cohorts Variable Vasopressin and Septic Shock Trial Cohort St. Pauls Hospital Cohort No SAE (n = 534) Any SAE (n = 63) p No SAE (n = 481) Any SAE (n = 52) p Age, yr 63 (5072) 69 (5475) 0.045 a 62 (4772) 64 (4873) 0.341 Gender: male, n (%) 320 (59.9) 33 (52.4) 0.249 307 (63.8) 31 (59.6) 0.549 Race: Caucasian, n (%) 449 (84.1) 51 (81.0) 0.524 374 (77.8) 42 (80.8) 0.618 Acute Physiology and Chronic Health Evaluation II 26 (2232) 28 (2334) 0.100 26 (2132) 29 (2434) 0.035 a Use vasopressor: NE 263 (49.3%) 30 (47.6%) 0.806 384 (79.8%) 38 (73.1%) 0.254 Maximum dose of NE on day 1 (g/min) 15 (926) 20 (1134) 0.016 a 12 (525) 15 (625) 0.593 Preexisting condition, n (%) Congestive heart failure 44 (8.2) 2 (3.2) 0.154 27 (5.6) 5 (9.6) 0.226 Chronic obstructive lung disease 97 (18.2) 8 (12.7) 0.281 78 (16.2) 10 (19.2) 0.578 Chronic renal failure 62 (11.6) 3 (4.8) 0.099 33 (6.9) 2 (3.8) 0.562 Liver disease 57 (10.7) 11 (17.5) 0.109 50 (10.4) 6 (11.5) 0.798 Chronic corticosteroid use 114 (21.3) 8 (12.7) 0.107 28 (5.8) 3 (5.8) 1 Initial hemodynamic Mean arterial pressure (mm Hg) 55 (5061) 56 (4863) 0.876 54 (5059) 54 (5060) 0.659 Heart rate (beats/min) 126 (110140) 130 (112142) 0.146 115 (95130) 105 (90130) 0.024 a Serum lactate (mmol/L) 2.2 (1.44.3) 2.8 (1.95.5) 0.035 a 2.3 (1.44.7) 2.9 (2.05.6) 0.054 rs28418396_AVPR1B TT/TA 150 (28.1%) 8 (12.7%) 0.009 a 134 (27.9%) 6 (11.5%) 0.011 a AA 384 (71.9%) 55 (87.3%) 347 (72.1%) 46 (88.5%) SAE = serious adverse event, NE = norepinephrine. a p < 0.05. Data are median (interquartile range) for continuous variables. p values were calculated with the use of Pearson chi-square test and Mann-Whitney U test. Anantasit et al 1816 www.ccmjournal.org August 2014 Volume 42 Number 8 had higher APACHE II than patients who did not have SAEs (29 vs 26, p = 0.035) and had lower heart rates (105 vs 115, p = 0.024) (Table 2). There were no other signicant differ- ences between groups. Regarding timing of SAEs (Supplemental Table 1, Supplemental Digital Content 1, http://links.lww.com/CCM/ A913), the mean time of SAEs after onset of vasopressor infusion was similar in the vasopressin and NE groups and ranged from 0 to 26 days. Time to SAE in the VASST and SPH cohorts is shown in Supplemental Figure 1 (Supplemental Digital Content 2, http://links.lww.com/CCM/A914). Nearly all SAEs occurred within 10 days of onset of shock treat- ment. There was no difference in time to SAE according to treatment group (vasopressin vs NE) in the VASST or SPH cohorts (Supplemental Fig. 2, Supplemental Digital Content 3, http://links.lww.com/CCM/A915; Supplemental Fig. 3, Supplemental Digital Content 4, http://links.lww. com/CCM/A916). Overall, 90-day mortality rates were 44.5% and 54.4% in VASST and SPH cohorts, respectively. Patients who had SAEs had higher 90-day (and 28-day) mortality rates (Fig. 1) and had greater organ dysfunction (cardiovascular, vasopressor use, ventilation, renal replacement, neurologic, hematologic, and hepatic) (Table 3). Cox regression analysis to adjust for clinical variables signicantly associated with SAEs (age, serum lactate, APACHE II, and maximum dose of NE on day 1) conrmed that patients who had serious events had higher mortality at 90 days (hazard ration [HR], 2.97; 95% CI, 2.204.00; p < 0.001 and HR, 1.89; 95% CI, 1.262.85; p = 0.002 in the whole VASST cohort [n = 779] and SPH, respectively) than patients without SAEs even after adjusting for these prognostic factors. Cox regression analysis to adjust for clinical variables signicantly associated with SAEs (age, serum lactate, APACHE II, maximum dose of NE on day 1, and AA genotype of rs 28418396) conrmed that patients who had serious events had higher mortality at 90 days (HR, 1.654; 95% CI, 1.152.39; p = 0.007 and HR, 2.08; 95% CI, 1.373.14; p < 0.001 in VASST and SPH, respectively) than patient without SAEs. Furthermore, Cox regression analysis to adjust for clinical variables signicantly associated with SAEs (age, serum lactate, APACHE II, maximum dose of NE on day 1, and any SAE) conrmed that patients who had AA genotype of rs28418396 had higher mortality at 90 days (HR, 1.41; 95% CI, 1.061.88; p = 0.018 and HR, 1.53; 95% CI, 1.132.07; p = 0.006 in VASST and SPH, respectively) than patient who had TA/TT geno- type of rs28418396. Comparing the vasopres- sin with NE groups in VASST and then in SPH, patients with SAEs had higher mortality and fewer DAF of organ dysfunc- tion in most comparisons except for the vasopressin group in SPH (Supplemental Table 2, Supplemental Digital Content 5, http://links.lww.com/CCM/ A917). The area under the curve of plasma vasopressin concentra- tion was not different between Figure 1. Kaplan-Meier survival curves of septic shock patients who had developed any serious adverse events (SAEs) compared with septic shock patients who had not developed SAEs in both discovery (Vasopressin and Septic Shock trial, VASST) and validation (St. Pauls Hospital, SPH) cohorts. Clinical Investigations Critical Care Medicine www.ccmjournal.org 1817 patients with and without SAEs (Fig. 2). As expected, the AUC of AVP level showed that patients in NE group had much lower AUC than those in the vasopressin group (Fig. 2). We successfully genotyped 268 tag SNPs in vasopressor path- way genes in VASST cohort. All SNPs were in Hardy-Weinberg equilibrium. In VASST, nine SNPs were signicantly associated with SAEs (Table 4). Of these, only rs28418396 was also signi- cant in the validation (SPH) cohort. We found that patients who had AA genotype of rs28418396 in NE group were statistically signicant increased risk of SAEs in both cohorts (p = 0.001 in VASST discovery cohort, which is signicant after Bonferroni correction; p = 0.04 in SPH validation cohort, single SNP vali- dation so not corrected in validation cohort) (Fig. 3). An adjusted analysis (multiple logistic regression) in the discovery cohort (VASST) using age, APACHE II, arterial lac- tate, and maximum dose of NE on day 1 as covariates showed that patients who had the AA genotype of rs28418396 SNP had signicantly more SAEs than patients who had TA/TT geno- types (AA vs TA/TT, VASST: adjusted odds ratio [OR], 2.27; 95% CI, 1.034.98; p = 0.041). Logistic regression analysis for SAEs in SPH validated that patients who had AA genotype of rs28418396 had greater risk of SAEs than patients who had TT/ TA genotypes of rs28418396 (AA vs TT/TA, adjusted OR, 2.99; 95% CI, 1.247.21; p = 0.014 after adjusting for age, serum lactate, and APACHE II). Patients who had AA genotype of rs28418396 in vasopressin group had signicant lower AUC of AVP level over the rst 7 days than patient who had TA/TT genotype (p = 0.022). DISCUSSION In this study, we found that 10% of patients with septic shock who received vasopressin or NE had SAEs in discovery and val- idation cohorts. Second, we found that patients who had SAEs had about double the mortality rates of patients who did not have SAEs. Third, we found that the area under the vasopres- sin concentration curve was not different between patients on vasopressin infusion with or without SAEs. Finally, we found that patients who had the AA genotype of rs28418396 SNP had signicantly higher rates of SAEs in both discovery and valida- tion cohorts. The SAE rates we found are somewhat lower when com- pared with other studies (6, 9). One reason could be use of dif- ferent denitions of SAEs in different studies. Different dosing of vasopressin and NE is not likely the explanation as the doses of vasopressin and NE of our study were similar (vasopressin dose was 0.010.03 U/min; mean maximum doses of NE were 26.7 and 24.6 g/min in VASST and SPH cohort, respectively) to other studies. TABLE 3. Mortality Rates and Morbidities of Patients With or Without Serious Adverse Events in the Discovery (Vasopressin and Septic Shock Trial) and Validation (St. Pauls Hospital) Cohorts Variable Vasopressin and Septic Shock Trial Cohort St. Pauls Hospital Cohort No SAE (n = 534) Any SAE (n = 63) p No SAE (n = 481) Any SAE (n = 52) p Outcome, n (%) 28-day mortality 168 (31.5%) 35 (55.6%) < 0.001 a 215 (44.7%) 34 (65.4%) 0.005 a 90-day mortality 228 (42.7%) 38 (60.3%) 0.008 a 251 (52.2%) 39 (75%) 0.002 a Length of ICU stay (d) 10 (516) 9 (319) 0.62 8 (415) 10 (421) 0.611 Days alive and free of organ dysfunction Cardiovascular 20 (024) 3 (021) < 0.001 a 11 (023) 4 (016) 0.006 a Vasopressor use b 20 (024) 3 (022) 0.001 a 18 (125) 7 (020) 0.004 a Ventilation c 10.5 (021) 0 (08) < 0.001 a 3 (020) 1 (09) 0.039 a Renal replacement 26 (628) 16 (128) 0.006 a 15 (228) 7 (123) 0.042 a Neurologic d 18 (025) 2 (018) < 0.001 a 22 (427) 9 (225) 0.007 a Hematologic e 25 (728) 19 (128) 0.005 a 21 (428) 10 (225) 0.031 a Hepatic 27 (728) 11 (128) 0.001 a 20 (328) 8 (127) 0.013 a Any organ failure 0 (010) 0 (02) 0.012 a 0 (00) 0 (00) 0.216 a SAE = serious adverse events. a p < 0.05. b Vasopressor use was defned as 5 g or more of dopamine/kg/min or any dose of norepinephrine, epinephrine, or phenylephrine. c Ventilation was defned as intubation and positive-pressure ventilation. d Neurologic was defned as Glasgow Coma Score < 12, prior to receiving sedation. e Hematologic was defned as new onset of coagulation defect or platelet count < 80,000/mm 3 . Data are median (interquartile range) for continuous data. p values were calculated with Pearson chi-square test and Mann-Whitney U test. Anantasit et al 1818 www.ccmjournal.org August 2014 Volume 42 Number 8 This study showed that patients with SAEs had higher (about double) mortality rate than patients without SAEs. Because this was an association study, it is not clear whether the SAEs were in some part causal of the increased mortality rates or whether the presence of SAEs simply identied sicker patients at increased risk of death. Some clinical markers were associated with increased risk of SAEs in one or both cohorts. For example, patients who had developed SAEs had a trend to higher serum lactate than patients without SAEs. Prior studies found that high serum lactate is a risk predictor of nonocclusive mesenteric isch- emia (21). Patients with SAEs also were older and had higher APACHE II than patients without SAEs. These simple clinical markers could be used to iden- tify patients at increased risk of SAEs while on vasopressin or NE infusions for septic shock. We found that the AA geno- type of rs28418396 SNP was sig- nicantly associated with SAEs in discovery (VASST) and vali- dation (SPH) cohorts. To our knowledge, this is the rst study to demonstrate that AA geno- type of rs28418396 SNP is a risk factor for SAEs in patients with septic shock. The rs28418396 is near the 5 untranslated region of the AVPR1b gene. AVPR1b gene sized is 7,200 bases in chromosome 1q32. AVP is pro- duced in the hypothalamus, stored in posterior pituitary, and released into the circula- tion (2). There is an impor- tant interaction between AVP and the adrenal axis in stress situations that is linked by the AVPR1b receptor (22). When vasopressin binds to the V1b receptor on corticotrophs in the anterior pituitary (coded for by the AVPR1b gene), adrenocor- ticotropin hormone (ACTH) is released (23). Septic shock acti- vates vasopressin release to sup- raphysiologic levels and then vasopressin levels decrease rap- idly (24). Furthermore, animal studies show that the activation of central vasopressin may be mediated by NE through 1- adrenergic receptors (25). NE also triggers the pituitary gland to release ACTH. The exact mechanism by which rs28418396 SNP of AVPR1b gene inuences any SAEs, particularly patients who received NE infu- sion, is unknown and requires further investigation. Plasma vasopressin levels were not associated with SAEs in septic shock patients. In particular for patients on vasopressin infusion, vasopressin levels were not different between patients with or without SAEs suggesting that simple pharmacokinetics and higher vasopressin levels were not associated with SAEs. Vasopressin secretion is complex and depends on blood pres- sure, plasma osmolarity, and blood volume (26), as well as hypercapnia, hypoxia, hyperthermia, pain, nausea, and mor- phine. Furthermore, many hormones are direct stimulators of vasopressin, such as acetylcholine, histamine, angiotensin Figure 2. The area under the plasma vasopressin concentration-time curve (AUC) in septic shock patients in the discovery (Vasopressin and Septic Shock trial) cohort at 24 hr and 7 days in the norepinephrine (NE) and arginine vasopressin (AVP) groups without (top) or with regard to the genotype of rs28418396 of AVPR1b. SAE = serious adverse events. Clinical Investigations Critical Care Medicine www.ccmjournal.org 1819 II, prostaglandins, dopamine, and, particularly, the adrenergic system. At low concentrations, NE increases vasopressin activ- ity; conversely, at high concentrations, NE inhibits vasopressin secretion (27). The half-life of vasopressin is approximately 10 minutes. Therefore, vasopressin levels are not good estimates of its production and release. This study showed that the area under the plasma concentration-time curve of vasopressin was not different between patients with or without SAEs in both vasopressin and NE groups. The clinical implications of our study are important. We suggest that the original VASST randomized controlled trial provides guidance on efcacy of vasopressin versus NE in that in the stratum of patients who had less severe shock (dened as NE infusion < 15 g/min), patients in the vasopressin group had lower mortality than patients in the NE group. Regarding safety, the original publication and the current study sug- gest that the risk of SAEs is similar for vasopressin versus NE. Furthermore, patients must be proactively monitored for SAEs because they are frequent and are associated with increased mortality. Second, we sug- gest that vasopressor infusions should be altered (decrease dose, switch to an alternative vasopressor, re-evaluate volume status, and consider administer- ing volume to allow vasopressor weaning). Third, if the genomic marker rs28418396 is validated further, then in future, patients could be assessed by measur- ing their genotype and altering vasopressor choice according to genotype. There are several limitations in this study. First, the valida- tion (SPH) cohort was a retro- spective chart review (which may underestimate SAEs seen in practice) and there were no plasma vasopressin level mea- surements. Second, this is an association study so we can- not conclude to what extent TABLE 4. Allele Frequency and Associations With Serious Adverse Events of Signicant Tag Single-Nucleotide Polymorphisms in Vasopressor Pathway Genes in the Discovery (Vasopressin and Septic Shock Trial) Cohort Single-Nucleotide Polymorphism_Gene Major/Minor Allele Minor Allele Frequency (n = 597) Hardy-Weinberg Equilibrium p Serious Adverse Event p rs28418396_AVPR1b A/T 0.14 0.538 0.034 rs11121816_AGTRAP G/T 0.40 0.156 0.031 rs11953730_LNPEPregion C/T 0.001 0.984 0.004 rs11958177_LNPEPregion A/G 0.001 0.984 0.004 rs2549779_LNPEPregion A/G 0.48 0.402 0.012 rs2549780_LNPEPregion A/G 0.48 0.807 0.030 rs17531248_LNPEPregion C/G 0.18 0.474 0.031 rs9127_LNPEPregion A/G 0.42 0.542 0.043 rs27302_LNPEPregion A/G 0.38 0.787 0.044 AVPR1b = arginine vasopressin receptor 1b, AGTRAP = angiotensin II type 1 receptorassociated protein, LNPEP = leucyl/cystinyl aminopeptidase. p value were calculated with the use of chi-square test for Hardy-Weinberg equilibrium and Breslow generalized Wilcoxon test for serious adverse events. Figure 3. Percentage of AA genotypes of rs28418396 single-nucleotide polymorphism in septic shock patients with or without serious adverse events (SAE) according to arginine vasopressin (AVP) or norepinephrine groups in discovery (Vasopressin and Septic Shock trial, VASST) and validation (St. Pauls Hospital, SPH) cohorts. *p = 0.001 in VASST and p = 0.04 in SPH. Anantasit et al 1820 www.ccmjournal.org August 2014 Volume 42 Number 8 the development of SAEs while on vasopressin or NE infu- sion contributed to increased mortality. Third, we could not directly address vasopressin production and release. We did, however, assess the relationship between plasma vasopressin levels and occurrence of SAEs because higher doses and levels of vasopressin could have caused greater vasoconstriction and so could have caused more ischemic SAEs. The lack of differ- ence in plasma vasopressin levels between those who did or did not have an SAE could dissociate the biological plausibility between SAE and use of vasopressor. CONCLUSIONS About 10% of patients with septic shock on vasopressin or NE infusion had SAEs. The development of SAEs identied patients with greatly increased (about double) mortality rates compared with patients who did not have SAEs. In patients on vasopressin infusion, vasopressin levels were not different between patients with or without SAEs suggesting that simple pharmacokinetics and higher vasopressin levels did not cause SAEs. Patients who had the AA genotype of rs28418396 SNP had signicantly higher rates of SAEs in both discovery and validation cohorts; the mechanism of this association requires further investigation. REFERENCES 1. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39:165228 2. Obritsch MD, Bestul DJ, Jung R, et al: The role of vasopressin in vaso- dilatory septic shock. Pharmacotherapy 2004; 24:10501063 3. Obritsch MD, Jung R, Fish DN, et al: Effects of continuous vasopres- sin infusion in patients with septic shock. Ann Pharmacother 2004; 38:11171122 4. Dnser MW, Mayr AJ, Tr A, et al: Ischemic skin lesions as a compli- cation of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors. Crit Care Med 2003; 31:13941398 5. Russell JA, Walley KR, Singer J, et al; VASST Investigators: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877887 6. Hall LG, Oyen LJ, Taner CB, et al: Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor ther- apy for septic shock. Pharmacotherapy 2004; 24:10021012 7. Ferguson-Myrthil N: Vasopressor use in adult patients. Cardiol Rev 2012; 20:153158 8. Annane D, Vignon P, Renault A, et al; CATS Study Group: Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: A randomised trial. Lancet 2007; 370:676684 9. Torgersen C, Dnser MW, Wenzel V, et al: Comparing two differ- ent arginine vasopressin doses in advanced vasodilatory shock: A randomized, controlled, open-label trial. Intensive Care Med 2010; 36:5765 10. van Haren FM, Rozendaal FW, van der Hoeven JG: The effect of vaso- pressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 2003; 124:22562260 11. Holmes CL, Walley KR, Chittock DR, et al: The effects of vasopressin on hemodynamics and renal function in severe septic shock: A case series. Intensive Care Med 2001; 27:14161421 12. Phillips KA, Veenstra DL, Oren E, et al: Potential role of pharmacoge- nomics in reducing adverse drug reactions: A systematic review. JAMA 2001; 286:22702279 13. Russell JA: Bench-to-bedside review: Vasopressin in the manage- ment of septic shock. Crit Care 2011; 15:226 14. Nakada TA, Russell JA, Wellman H, et al: Leucyl/cystinyl aminopepti- dase gene variants in septic shock. Chest 2011; 139:10421049 15. Nakada TA, Russell JA, Boyd JH, et al: Beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. Am J Respir Crit Care Med 2010; 181:143149 16. Wu CK, Tsai CT, Chang YC, et al: Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure. J Hypertens 2009; 27:502507 17. Nakada TA, Russell JA, Boyd JH, et al: Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock. Crit Care Med 2011; 39:16411648 18. Bone RC, Balk RA, Cerra FB, et al: Defnitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:16441655 19. Sutherland AM, Walley KR, Manocha S, et al: The association of inter- leukin 6 haplotype clades with mortality in critically ill adults. Arch Intern Med 2005; 165:7582 20. Sibbald WJ, Vincent JL: Round table conference on clinical trials for the treatment of sepsis. Intensive Care Med 1995; 21:184189 21. Groesdonk HV, Klingele M, Schlempp S, et al: Risk factors for nonoc- clusive mesenteric ischemia after elective cardiac surgery. J Thorac Cardiovasc Surg 2013; 145:16031610 22. Hernando F, Schoots O, Lolait SJ, et al: Immunohistochemical local- ization of the vasopressin V1b receptor in the rat brain and pituitary gland: Anatomical support for its involvement in the central effects of vasopressin. Endocrinology 2001; 142:16591668 23. Lolait SJ, Stewart LQ, Jessop DS, et al: The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology 2007; 148:849856 24. Sharshar T, Blanchard A, Paillard M, et al: Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31:17521758 25. Xu S, Guo S, Jiang X, et al: The role of norepinephrine and nitric oxide in activities of rat arginine vasopressin neurons in response to immune challenge. Neurosci Lett 2005; 383:231235 26. Delmas A, Leone M, Rousseau S, et al: Clinical review: Vasopressin and terlipressin in septic shock patients. Crit Care 2005; 9:212222 27. Leng G, Brown CH, Russell JA: Physiological pathways regulating the activity of magnocellular neurosecretory cells. Prog Neurobiol 1999; 57:625655